{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"3.2","value":"1.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the period from study entry until disease progression, death, or the last date of contact. Progression was based on RECIST 1.1. RECIST 1.1 defines progressive disease as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions or unequivocal progression of non-target lesions is also considered progression.","dispersionType":"90% Confidence Interval","groups":[{"description":"MLN8237, 50 mg, taken by mouth twice daily on Days 1-7. One cycle is 3 weeks long (21 days). CT or MRI imaging for response every other cycle (every 6 weeks). Treatment may continue until disease progression or adverse effects prohibit further therapy.","id":"OG000","title":"MLN8237"}],"paramType":"MEDIAN","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"every other cycle for the first 6 months; then every 3 months thereafter until disease progression is confirmed; up to 5 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}